| 70.02 -9.84 (-12.32%) | 01-23 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 91.38 |
1-year : | 98.76 |
| Resists | First : | 78.24 |
Second : | 84.55 |
| Pivot price | 78.69 |
|||
| Supports | First : | 68.01 |
Second : | 56.59 |
| MAs | MA(5) : | 78.91 |
MA(20) : | 78.17 |
| MA(100) : | 60.07  |
MA(250) : | 46.78 |
|
| MACD | MACD : | 1.2 |
Signal : | 2 |
| %K %D | K(14,3) : | 50.2 |
D(3) : | 65.9 |
| RSI | RSI(14): 34.7 |
|||
| 52-week | High : | 84.55 | Low : | 26.2 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ APGE ] has closed below the lower bollinger band by 22.6%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 18.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 78.94 - 79.42 | 79.42 - 79.77 |
| Low: | 67.02 - 67.58 | 67.58 - 67.99 |
| Close: | 69.28 - 70.11 | 70.11 - 70.73 |
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Fri, 23 Jan 2026
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Fri, 23 Jan 2026
Apogee Therapeutics (NASDAQ:APGE) Trading Down 10.2% Following Insider Selling - MarketBeat
Thu, 22 Jan 2026
Apogee Therapeutics (NASDAQ:APGE) Director Fairmount Funds Management Llc Sells 1,750,000 Shares - MarketBeat
Thu, 22 Jan 2026
Apogee Therapeutics stock downgraded by RBC Capital on valuation concerns By Investing.com - Investing.com Nigeria
Wed, 21 Jan 2026
Apogee Therapeutics: 2026 Inflection Point In Immunology (NASDAQ:APGE) - Seeking Alpha
Sat, 17 Jan 2026
CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 55 (M) |
| Shares Float | 49 (M) |
| Held by Insiders | 6.1 (%) |
| Held by Institutions | 112.9 (%) |
| Shares Short | 8,660 (K) |
| Shares Short P.Month | 7,900 (K) |
| EPS | -4.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 9.89 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25.3 % |
| Return on Equity (ttm) | -38.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.15 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -232 (M) |
| Levered Free Cash Flow | -143 (M) |
| PE Ratio | -15.99 |
| PEG Ratio | 0 |
| Price to Book value | 7.07 |
| Price to Sales | 0 |
| Price to Cash Flow | -16.52 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|